Company intelligence / Profile preview

CancerMedica

Ownership: Private
Development stage: Other

Overview

CancerMedica is a biotechnology company focused on the development of innovative oncology therapeutics. The company specializes in identifying and advancing novel small molecule inhibitors and immunotherapies designed to target specific pathways in cancer cell proliferation and immune evasion. Currently in the pre-clinical stage, CancerMedica aims to bridge the gap between laboratory discovery and clinical application through rigorous research and strategic development. Their pipeline is primarily directed toward addressing unmet needs in solid tumors and various hematologic malignancies.

Therapeutic areas: Oncology
Modalities: Small moleculeImmunotherapy
Industry: Biotech

Beyond the preview

Go deeper on CancerMedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CancerMedica.

Explore the full profile